EXPERIAN PLC/ADR (OTCMKTS:EXPGY) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.
This table compares EXPERIAN PLC/ADR and Hikma Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares EXPERIAN PLC/ADR and Hikma Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|EXPERIAN PLC/ADR||$4.86 billion||5.89||$695.00 million||$0.97||32.40|
|Hikma Pharmaceuticals||$2.07 billion||3.00||$282.00 million||$1.38||18.70|
EXPERIAN PLC/ADR has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than EXPERIAN PLC/ADR, indicating that it is currently the more affordable of the two stocks.
EXPERIAN PLC/ADR pays an annual dividend of $0.61 per share and has a dividend yield of 1.9%. Hikma Pharmaceuticals does not pay a dividend. EXPERIAN PLC/ADR pays out 62.9% of its earnings in the form of a dividend.
Risk and Volatility
EXPERIAN PLC/ADR has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.
Institutional & Insider Ownership
0.3% of EXPERIAN PLC/ADR shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and target prices for EXPERIAN PLC/ADR and Hikma Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
EXPERIAN PLC/ADR beats Hikma Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About EXPERIAN PLC/ADR
Experian plc, together with its subsidiaries, operates as an information services company. The company offers credit services, such as holding, protecting, and managing data that help businesses and organizations to lend, as well as prevent frauds. Its credit services also holds information of people and businesses that have repaid credit in the past; and provides credit reports used by various businesses, such as banks, automotive dealers, healthcare providers, and retailers. The company also provides software and analytics solutions that help clients in lending, as well as detecting and minimizing frauds, and complying with legal requirements. In addition, it offers marketing services, which include data management and analytics that enable businesses to plan, build, and deliver their marketing campaigns. Further, the company provides online financial education and debt resolution services that help people to understand and manage their financial position, while protecting themselves from fraud and identity theft. Additionally, it engages in the development of intellectual property; and provision of administrative services. Experian plc serves customers in financial service, direct-to-consumer, healthcare, retail, automotive, software and professional services, telecommunications and utility, insurance, media and technology, government and public, and other sectors in North America, Latin America, the United Kingdom, and Ireland, as well as rest of the Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Experian Group Limited and changed its name to Experian plc in July 2008. Experian plc was founded in 1803 and is headquartered in Dublin, Ireland.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. The Generics segment develops and sells oral and other non-injectable generic products for retail market. The Branded segment develops, manufactures, and markets branded generics and in-licensed products to retail and hospital markets. The company offers products in various therapeutic areas, including respiratory, oncology, pain management, anti-infectives, cardiovascular, diabetes, and central nervous system. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Receive News & Ratings for EXPERIAN PLC/ADR Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for EXPERIAN PLC/ADR and related companies with MarketBeat.com’s FREE daily email newsletter.